

National Institute for Health and Care Excellence
IP1437 Endobronchial nerve ablation for chronic obstructive pulmonary disease

IPAC date: 14 October 2021

| Com . no. | Consultee name and organisation | Sec. no. | Comments | Response |
|-----------|---|----------|--|--|
| | | | | Please respond to all comments |
| 1 | Consultee 1 British Thoracic Society | 1.2 | The British Thoracic Society welcomes the NICE recommendation for further RCTs of endobronchial nerve ablation. There are few current treatment options for people with COPD yet many thousands living with the symptoms of COPD. A new safe intervention that could improve quality of life, exacerbations and patient reported outcomes is most definitely needed. | Thank you for your comment. |
| 2 | Consultee 1 British Thoracic Society | 1.2 | Parallel lung function assessment to the outcomes proposed would provide added information from the RCTs. | Thank you for your comment. Additional wording has been added to section 1.2: <i>“Further research should be randomised controlled trials comparing the procedure with sham treatment. It should report details of patient selection, and short and long-term functional outcomes including lung functional outcomes, quality of life and patient-reported outcomes, incidence of exacerbations and hospital admissions, and all adverse events.”</i> |

“Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.”